Arterial Vessel Articles & Analysis
14 news found
” Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures including ducts – for surgical and interventional procedures. About Amsel Medical Corporation Amsel Medical Corporation is a medical device venture ...
Gandras et al. evaluated[i] the ability of Embrace HES to achieve hemostasis in a porcine mesenteric artery hemorrhage model that replicates injury in humans. Results demonstrated that Embrace HES achieved complete, rapid, and durable embolization in 100% of the injured arteries with a mean delivery time of 5.3 minutes. ...
ArterioSorb is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). CAD is the leading cause of death both in the UK and worldwide, responsible for more than 73,000 deaths in the UK each year. ArterioSorb™ is a next-generation bioresorbable cardiovascular scaffold (BRS, stent), to ...
” Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures including ducts – for surgical and interventional procedures. About Amsel Medical Corporation Amsel Medical Corporation is a medical device venture ...
” Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures including ducts – for surgical and interventional procedures. About Amsel Medical Corporation Amsel Medical Corporation is a medical device venture ...
” Amsel Medical’s SCureClamp™ with Interdigitation Occlusion Technology (iDOT™) is designed to easily and securely close vessels – veins, arteries, and tubular structures including ducts – for surgical and interventional procedures. About Amsel Medical Corporation Amsel Medical Corporation is a medical device venture ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
Secondary endpoints include measures of the implants’ ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major cardiovascular events. ...
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif. – March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of ...
Drug-eluting stents cage the coronary arteries and hinder this physiological response. DynamX is the first metallic coronary artery implant to demonstrate positive adaptive remodeling of the vessel. ...
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents International Trial to Compare Bioadaptor, a MILPITAS, Calif. ...
(CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
About the Amsel Occluder Device The Amsel Occluder Device is designed to easily and securely close blood vessels (veins or arteries) as well as tubular structures during open surgical procedures. ...
When compared with monotherapy, the combination therapy increased densities of key blood vessels, arteries, and smooth muscle cells in vascular walls. “HUCBCs are a source for blood stem cells, endothelial cell precursors, mensenchymal cell progenitors, and other multipotent and pluripotent stem cells,” said Kuzmin-Nichols. ...